glp 1 approved for mash Emerging Role of GLP-1 Receptor Agonists the Treatment of Efficacy and safety of GLP-1

The Unpublished Phase I Trial: A Critical Look A pivotal point of discussion is the Phase I clinical trial for BPC-157 in patients with IBD, registered on ClinicalTrials.gov

We then went a step further and demonstrated a protective effect compared to statins, which also have been thought to be anti-inflammatory and protective across numerous organ systems. People taking GLP-1 receptor agonists also had a lower risk of wet AMD compared with people taking statins, insulin and aspirin, and a lower risk of primary open-angle glaucoma compared with people taking metformin, insulin and aspirin

The information in this article is for educational use, and not intended to substitute professional medical advice, diagnosis, or treatment and should not be used as such.

Its triple-agonist mechanism means it already covers three of the most important metabolic pathways in a single injection